Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73$410 - $420 million –– Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY® Award-winning singer-songwriter, Carly Pearce –– Kiniksa expects to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET to ...